4 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 2 |
Follow Otonomy, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OTO-413 in Subjects With Speech-in-Noise Hearing Impairment OTO-413, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 110 | 2019-10-01 | 2022-10-27 |
| OTO-313 in Subjects With Subjective Tinnitus OTO-313, Placebo - Tinnitus, Subjective | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 43 | 2019-04-04 | 2022-12-23 |
| OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement OTO-201, Placebo, Sham - Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement | Phase 1 | Completed | Otonomy, Inc. | 83 | 2012-12-01 | 2013-06-19 |
| OTO-104 for Meniere's Disease OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg - Meniere's Disease | Phase 1 | Completed | Otonomy, Inc. | 44 | 2010-03-01 | 2011-06-08 |
Hearing Loss (2) · Tinnitus (2) · Hearing Loss, Hidden (1) · Hearing Loss, Sensorineural (1) · Meniere Disease (1) · Vertigo (1)
Ciprofloxacin (1) · Steroids (1) · salicylhydroxamic acid (1)
United States (4)
Carl LeBel, PhD (2)